Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)

Clinical trial NCT00486720 · TERMINATED

Trial details

NCT number: NCT00486720
Sponsor: Merck Sharp & Dohme LLC
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndromes Blood Disease Bone Marrow Disease

Start date: 2007-06-01
Primary completion: 2009-07-01
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.